Can Finerenone Alter Glomerular Disease Trajectory? - Top-Institutions - MDSpire

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 4 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    The George Institute for Global Health
    The George Institute for Global Health

    Sydney, New South Wales

    Key Differentiators

    • Nephrology

  • #2

    University of New South Wales
    University of New South Wales

    Sydney, New South Wales

    Key Differentiators

    • Nephrology

  • #3

    University Medical Center Groningen
    University Medical Center Groningen

    Groningen, Groningen

    Key Differentiators

    • Nephrology

  • #4

    University of Glasgow
    University of Glasgow

    Glasgow, Scotland

    Key Differentiators

    • Nephrology

  • #5

    Osaka University Graduate School of Medicine
    Osaka University Graduate School of Medicine

    Osaka, Osaka

    Key Differentiators

    • Nephrology

Original Source(s)

Can Finerenone Alter Glomerular Disease Trajectory?

  • by Kathryn Wighton

  • June 5, 2026

Related Content

FDA Names PreCheck Participants

Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.

FDA Grants Traditional Approval to Iptacopan in Primary IgAN

Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

Hemodynamic Instability in Intubation May Be Predictable

Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.